Clinical Trial

A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated September 30, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a single-site prospective study to describe efficacy endpoints of single agent memantine in patients with unresectable, locally advanced, or metastatic HCC otherwise not deemed candidates for intensive systemic therapy. In addition to the primary endpoint and multiple secondary efficacy endpoints, we will describe changes in quality of life on treatment over time.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-08-18; most recent amendment 2025-09-26.
Status change: Not Yet Recruiting → Recruiting 2023-09-19
Trial Details
NCT Number NCT06007846
Lead Sponsor Inova Health Care Services
Conditions Hepatocellular Carcinoma, Cirrhosis
Enrollment 12 participants
Start Date 2023-07-31
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-30